Updated Jul 16, 2026
Goff Brian has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $1.59M.
Brian Goff is the Chief Executive Officer and Director of Agios Pharmaceuticals, Inc., a biopharmaceutical company focused on developing medicines for rare diseases. He has been involved in the company's strategic direction and operational management.
| Role | Chief Executive Officer, Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-10 | NTLA | Intellia Therapeutics, Inc. | A — Grant or award | 9.2K | $0.00 | |
| 2026-04-06 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 6.6K | $34.71 | $229K |
| 2026-04-06 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise [10b5-1] | 13.5K | $0.00 | |
| 2026-04-06 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 12.5K | $34.71 | $433K |
| 2026-04-06 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise [10b5-1] | 25.5K | $0.00 | |
| 2026-03-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 5.9K | $28.96 | $171K |
| 2026-03-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise [10b5-1] | 13.0K | $0.00 | |
| 2026-03-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 8.3K | $28.96 | $239K |
| 2026-03-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise [10b5-1] | 18.0K | $0.00 | |
| 2026-03-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale [10b5-1] | 3.9K | $28.96 | $112K |
| 2026-03-03 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise [10b5-1] | 8.5K | $0.00 | |
| 2025-08-08 | AGIO | AGIOS PHARMACEUTICALS, INC. | S — Open-market sale | 11.1K | $36.67 | $406K |
| 2025-08-08 | AGIO | AGIOS PHARMACEUTICALS, INC. | M — Option exercise | 22.7K | $0.00 |
Brian Goff is the Chief Executive Officer and Director of Agios Pharmaceuticals, Inc., a biopharmaceutical company focused on developing medicines for rare diseases. He has been involved in the company's strategic direction and operational management.…
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 6 open-market sales ($1.59M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Goff Brian profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.